Publications
6 publications
Funding
4 grants
Active
4 grants- KPU10CA180886-12COG NCTN Network Group Operations CenterNational Cancer Institute · 2026–2032 · via Children's Oncology Group
- PIHHWF 250646-03Combination studies of the LSD1 inhibitor IMG-7289 in pediatric relapsed and refractory acute myelogenous leukemiaHyundai Hope on Wheels Foundation · 2025–2027
- Co-IKL2TR002385-06Clinical and Translational Science Center - KL2National Center for Advancing Translational Sciences · 2022–2027
- KPCOG 264538WWWW Foundation, Inc: COGFndn_NY018_2026_QuadW_CSBAO_Tissue IncentivesWWWW Foundation INC dba QuadW · 2025–2026 · via Children's Oncology Group
Clinical research
3 studies
Active
3 studies- PINCT06124157An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic LeukemiaPHASE2 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2026)B Acute Lymphoblastic Leukemia
- PINCT06317662A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of VenetoclaxPHASE2 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2026)Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia
- PINCT03959085A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyPHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2024)B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia; Mixed Phenotype Acute Leukemia; Testicular Leukemia